We are live on ! Find out more

Pfizer

PFE

Market cap $174B

30.45 USD

-0.22

0.72%

At close Updated Nov 3, 1:27 PM EST

1 day

-0.72%

5 days

3.26%

1 month

11.09%

3 months

21.65%

6 months

15.78%

Year to date

20.93%

1 year

23.48%

5 years

-32.06%

10 years

7.37%

About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Employees: 75,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.9%

Neutral 30.3%

Negative 15.7%

24/7 Wall Street

UPS's $5.4 Billion Dividend Bill Exceeded Its Free Cash Flow. Is the Payout at Risk?

Four stocks are paying out billions in dividends that their cash flows can barely support, and the gap between what investors expect and what the business can actually deliver keeps widening.

UPS's $5.4 Billion Dividend Bill Exceeded Its Free Cash Flow. Is the Payout at Risk?

Zacks Investment Research

Q3 Earnings & JOLTS Report on Midterm Voting Day

Early voting has seen some 60+ million Americans take to the ballot this year -- far ahead of normal levels of midterm voting.

Q3 Earnings & JOLTS Report on Midterm Voting Day

Zacks Investment Research

Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research

PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance

Pfizer beats third-quarter earnings and revenue estimates, driven by strong non-COVID product sales, and increases its 2026 guidance.

PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance

The Motley Fool

Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction

Revenue was flat at $16.6 billion, with COVID and Prevnar sales falling while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena grew. Pfizer raised its full-year revenue and adjusted EPS guidance.

Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction

Zacks Investment Research

Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates

Pfizer (PFE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.87 per share a year ago.

Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates

The Motley Fool

Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?

Pfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts. The company experienced 32% growth from launched and acquired products, highlighting its underrated growth potential.

Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?

Investors Business Daily

Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFO

Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.

Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFO

Pfizer Raises Forecast on Momentum With New Products

Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.

Pfizer Raises Forecast on Momentum With New Products

Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates

Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.

Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates

See News Rankings

Price charts implemented using Lightweight Charts™